Anti-C5b-9 + C5b-8 [aE11] Biotin conjugated antibody (ab237699) mouse monoclonal antibody that is used to detect C5b-8 in ELISA. Suitable for Baboon, Horse, Human, Pig samples.
pH: 7.4
Preservative: 0.0975% Sodium azide
Constituents: 0.81% Sodium chloride, 0.16% Sodium phosphate
ELISA | |
---|---|
Human | Expected |
Baboon | Expected |
Horse | Expected |
Pig | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Pig, Baboon, Human, Horse | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. C5a anaphylatoxin. Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
C7, C8A, C6, C9
CPAMD4, C5, Complement C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
Anti-C5b-9 + C5b-8 [aE11] Biotin conjugated antibody (ab237699) mouse monoclonal antibody that is used to detect C5b-8 in ELISA. Suitable for Baboon, Horse, Human, Pig samples.
pH: 7.4
Preservative: 0.0975% Sodium azide
Constituents: 0.81% Sodium chloride, 0.16% Sodium phosphate
ab237699 binds both membrane-bound MAC (active) and fluid-phase SC5b-9 complexes (inactive).
The aE11 monoclonal was first reported to bind to a neoepitope exposed on polymerized C9 when incorporated into the human terminal complement complex (PubMed ID: 4035298). It was subsequently shown that this antibody also cross reacts with the C5b-8 complex and purified C8 alpha-gamma. It does not react with native C9 or C8 proteins (PubMed ID: 2424021).
Biotinylated
The C5b-9 complex also known as the membrane attack complex (MAC) plays an important role in the immune system specifically in the complement cascade. This complex forms as a result of the sequential interaction of complement proteins C5b C6 C7 C8 and multiple C9 molecules creating a pore in the membrane of target cells leading to cell lysis. The C5b-8 serves as an intermediary in the formation of the C5b-9 complex and contributes to the initial assembly of the membrane attack complex. Expression of these components predominantly occurs on the surface of lymphocytes and activated macrophages though the exact mass of the assembled complex is less often quoted in standard references.
C5b-9 disrupts cellular homeostasis by forming transmembrane channels that permit unregulated ion movement. This function is pivotal in innate immunity where it eliminates virally infected and neoplastic cells. The C5b-9 complex forms through progressive recruitment and insertion of complement proteins into pathogenic membranes with each molecule one step closer to full assembly and execution of its lytic activity. In many immune system-related literature it represents terminal complement complexation signifying the endpoint of complement-mediated cytotoxicity.
C5b-9 is an integral component of the complement system's terminal pathway. This pathway escalates from the activation of C3 to the cleavage of C5 with C5b serving as an anchor for further protein assembly. The complement cascade also intersects with coagulation pathways bridging roles between immune defense and clotting functions. In this pathway association with proteins such as C3b and C6 is essential for initiating and propagating complex formation and ultimately cellular destruction.
The C5b-9 complex has notable involvement in autoimmune diseases and renal disorders. Paroxysmal nocturnal hemoglobinuria a condition characterized by red blood cell lysis directly involves excessive C5b-9 deposition due to defective complement regulation on host cells. Similarly atypical hemolytic uremic syndrome which results in kidney damage often links to mutations affecting regulators of C5b-9 activity showing the complex's contribution to pathogenesis. Employing therapeutic strategies researchers often target components like C5 and C9 to mitigate the harmful overactivation or misdirection of this complement activity.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com